Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SEC's website at www.sec.gov or by request at Dawson James Securities, Inc. by e-mailing placements@djsiny.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's cu
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 Perrigo ... commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL ... acquire Perrigo. "Our views of Mylan,s offer ... to be, based on our Board,s careful reflection of ... depend on the limited choices that Mylan has allowed ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 ... announced that its shareholders have approved Mylan,s proposed ... ; TASE) and the related issuance of Mylan ... general meeting of shareholders held today. The transaction ... the extraordinary general meeting. In addition, the transaction ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Calif., Sept. 28th, 2011  Cardiac Network, Inc. (Other ... a cardiac monitoring company located in Palm Desert, CA, ... LLC (PCI), today announces that it is completing the ... new Central Monitoring System, as described below, was built ...
... Inc. (NASDAQ: QCOR ) today announced preliminary ... 2011. The Company announced the estimated metrics in conjunction ... Don M. Bailey, President and Chief Executive Officer of ... a.m. BT, 3:00 a.m. ET.  To listen to the ...
Cached Medicine Technology:Cardiac Network is Near Completion of a New Monitoring System and Website 2Cardiac Network is Near Completion of a New Monitoring System and Website 3Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011 2Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011 3Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011 4Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011 5
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... IN (PRWEB) , ... August 28, 2015 , ... ... benefits advisory organization, is pleased to welcome TJS Insurance Group as its newest ... employees and clients guides them and keeps them focused on their goals. Within ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... swift actions to be taken in order to ease the stress on the ... scientists have yet to understand fully the real cause of global warming and urges ...
(Date:8/28/2015)... MA (PRWEB) , ... August 28, 2015 , ... ... International, Inc. ’s online medical consultations result in high percentages of change to ... by the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s ...
Breaking Medicine News(10 mins):Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... may be possible with many low energy treatments than ... ,The results of this study were published in ... eight participants over a three-month period during which they ... regeneration treatments are done to reduce wrinkles and for ...
... of 654 new cases of dengue fever were reported across ... average of 400 new //cases a day last week, Paraguay's ... Nicanor Duarte Frutos has not yet declared the epidemic to ... declaration. ,Dengue fever is a viral infection ...
... with a condition that is a strong genetic predictor ... genetic counseling or cancer screening. //According to a recent ... screening rates could be improved if physicians provided stronger ... screening to their patients. ,“We studied families with ...
... New Delhi: The eradication of neglected tropical diseases should ... the World Health Organization (WHO).// ,Many people ... leprosy, lymphatic filaria, leishmaniasis and yaws. Dengue is emerging ... ,"These diseases cause great suffering and ill-health and have ...
... - A new study by researchers from Queen's University ... eye movement tests in the diagnosis of fetal alcohol ... called FASD affects children when mothers have consumed alcohol ... tasks, could help effectively measure FASD in children, the ...
... approved meat and milk from cloned animals while it conducts ... its customers and consumers don't want milk from cloned animals. ... among dozens of other brands. ,"Numerous surveys ... products that contain milk from cloned cows and Dean Foods ...
Cached Medicine News:Health News:WHO Urges Higher Priority for Neglected Diseases 2Health News:Milk from Cloned Cows is Not Welcome at the Nation's Biggest Milk Company 2
The Simpulse®VariCare™ System provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support....
... Staple is a novel shape memory alloy bone ... of its Nitinol construction, the prongs of the ... upon application of a heating current. This results ... response of bone and cause adjustable compression across ...
... The Biomet ... is ideally suited ... This second-generation nail ... sharing fixation that ...
... SOF'WIRE Cable System provides immediate, stable, ... to conventional monofilament wire, SOF'WIRE is ... with ease and reproducibility. Stainless Steel ... optimal strength, durability and conformity. ...
Medicine Products: